6-N-烷基-6-氮杂-2-氧代-3-氧杂-4-甲氧基-双环[3.1.0]己烷的合成、立体化学及抗癌活性研究

以3-溴-5-甲氧基-2(5H)-呋喃酮和伯胺为原料,在均相中用三乙胺作碱性催化剂,可以得到一对非对映异构体(1Z,4E,5Z)-6-N-烷基-6-氮杂-2-氧代-3-氧杂-4-甲氧基-双环[3.1.0]己烷(4)和(1Z,4Z,5Z)-6-N-烷基-6-氮杂-2-氧代-3-氧杂-4-甲氧基-双环[3.1.0]己烷(5).目标分子4和5经IR,1HNMR,13CNMR,EIMS进行了表征,并做了结肠癌细胞(HCT-8)、肝癌细胞(BEL-7402)、人胃癌细胞(BGC-823)、肺腺癌细胞(A549)和人卵巢癌细胞(A2780)的抗癌活性实验,其中5c和5d对HCT-8,BGC-823,A549和A2780等癌细胞有一定的抑制作用.此研究结果不仅丰富了该领域研究的理论基础,而且对某些新型药物的研制具有一定的指导意义.     

5-二氰亚甲基-4-二环丙亚甲基-3-[1-(2, 5-二甲基-3-呋喃基)亚乙基]四氢呋喃-2-酮的合成

报道俘精酸酐类化合物(E/Z)4-二环丙亚甲基-3-[1-(2, 5-二甲基-3-呋喃基)亚乙基]四氢呋喃-2, 5-酮的拆分, 及(E)和(Z)-5-二氰亚甲基-4-二环丙亚甲基-3-[1-(2, 5-二甲基-3-呋喃基)亚乙基]四氢呋喃-2-酮 4(E)和4(Z)的合成, 并对它们的光致变色特性进行了初步研究。     

4-氧代-2-亚胺基噻唑烷-5-亚基乙酸乙酯类化合物的设计、合成及抗癌活性（英文）

以胺、异硫氰酸酯和炔酯为原料,通过三组分偶联环化制备了一系列4-氧代-2-亚胺基噻唑烷-5-亚基乙酸乙酯类化合物.采用噻唑蓝(MTT)法研究了目标化合物对人肝癌细胞Hep G2和人乳腺癌细胞MCF-7的体外抗癌活性,结果发现大多数化合物显示出明显的抗癌活性.与顺铂相比,(Z)-2-((Z)-2-((3,4-二氯苯基)亚氨基)-3-(3-(4-甲基哌嗪-1-基)丙基)-4-氧代噻唑烷-5-亚基)乙酸乙酯(4r)表现出最好的细胞毒性,对Hep G2和MCF-7的IC50值分别为0.88和0.80μmol/L,并且讨论了药物的初步构效关系.这些化合物对肿瘤细胞具有良好的生物活性,是一类有应用前景的化学治疗药物,值得进行后续研究.     

5-二氰亚甲基-4-二环丙亚甲基-3-[1-(2,5-二甲基-3-呋喃基)亚乙基]四氢呋喃-2-酮的合成

报道俘精酸酐类化合物(E/Z)4-二环丙亚甲基-3-[1-(2,5-二甲基-3-呋喃基)亚乙基]四氢呋喃-2,5-酮的拆分,及(E)和(Z)-5-二氰亚甲基-4-二环丙亚甲基-3-[1-(2,5-二甲基-3-呋喃基)亚乙基]四氢呋喃-2-酮4(E)和4(Z)的合成,并对它们的光致变色特性进行了初步研究。     

氯化亚铜催化3-氯-1-丁烯异构为1-氯-2-丁烯研究

采用一价铜盐为催化剂、二甲基甲酰胺为溶剂,在均相体系中催化3-氯-1-丁烯异构化生成1-氯-2-丁烯.考察了溶剂、反应温度、催化剂种类和加入量对反应的影响,研究发现反应温度和催化剂的加入量对异构化反应有较大影响.在最优条件3-氯-1-丁烯1 mL,二甲基甲酰胺9 mL,CuCl 0.10 g,60℃反应5 h,产物和原料的浓度比为3.88 mmol L-1.采用在线红外光谱对反应过程进行监测,检测到有红外吸收峰在反应过程中先增加后减少的变化过程,提出了可能的反应机理.     

5-硝基-2H-四唑的合成、反应性及产物晶体结构的研究

5-氨基四唑(1)经过重氮化反应得到5-硝基四唑(5),5与甲醛反应得到2-羟甲基-5-硝基四唑(6),6与HCl或HBr反应分别得到5-5氯代四唑(7)和5-溴代四唑(8),采用MS,IR,1H NMR,13C NMR等技术对这些化合物进行了表征.用X射线单晶衍射法测定了化合物5-硝基四唑钠(4),5和6的晶体结构.化合物4属于三斜晶系,P-1空间群;化合物5和6均属于单斜晶系,P21空间群,化合物6的晶胞参数a=0.66131(18)nm,b=0.54905(15)nm,c=0.7566(2)nm,Z=2,V=0.27470(13)nm3,Dc=1.754g/cm3,F(000)=128,μ=0.160mm-1.     

新方法合成（Z）-5-氟-2-甲基-1-[（4-甲基亚磺酰苯基）亚甲基]-1H-茚-3-乙酸及其X-单晶衍射分析

以对甲亚磺酰基苄溴为原料，通过4步反应合成得到立体专一性的Z式构型产物（Z）-5-氟-2-甲基-1-[（4-甲基亚磺酰苯基）亚甲基]-1H-茚-3-乙酸（Sulindac舒林酸）。X-单晶衍射分析舒林酸分子中共存有强和弱的分子间氢键。     

4-叔丁基-5-(1,2,4-三唑-1-基)-2-苄亚氨基噻唑的合成、晶体结构和抗菌活性

以履代(口片)吶酮,经1,2,4-三唑取以、溴以、硫脲环合得到4-叔丁基-5-(1,2,4-三唑-1-基)-2-氨基噻唑;再与芳醛缩合合成一系列新4-叔丁基-5-(1,2,4-三唑-1-基)-2-苄亚氨基噻唑(5).用单晶X射线衍射测定了化合物5a的晶体结构.化合物5a的晶体属三斜晶系,空间群以P-1,晶胞参数以:a=0.72749(12)nm,b=0.93463(15)nm,c=1.3398(2)nm,α=70.185(2)°,β=75.669(2)°,γ=73.611(2)°;V=0.8105(2)nm3,Z=2,Dc=1.342g/cm3,F(000)=344,R1=0.0431,wR2=0.1611,S=1.01.生物活性实验结果表明:化合物5c(25mg/L)对小麦赤霉病菌、稻曲病菌、对黄瓜灰霉病菌和稻纹枯病菌的抑制率分别以100%,100%,82.8%和80.3%.化合物5d(25mg/L)对稻纹枯病菌、油菜菌核病菌、小麦赤霉病菌和稻曲病菌的抑制率分别以100%,95.5%,100%和100%.化合物5e(25mg/L)对小麦赤霉病菌的抑制率以100%.5d对小麦赤霉病菌、油菜菌核病菌和水稻纹枯病菌的EC50值分别以1.16,1.38和1.47mg/L.     

膦、胂叶立德的化学与应用 XII. 对硝基苯基亚甲基三苯基膦、胂与2-全氟炔酸甲酯的反应以及(Z)3-全氟烷基 4-对硝基苯基-3-丁烯酸甲酯的立体专一性合成

溴化对硝基苄基三苯基 (1a)、 (1b)在碳酸钾存在下与2-全氟炔酸甲酯(2)在常温下反应, 生成加合物3(当M=As时)或3和4的混合物(当M=P时), 其中3的含量随反应温度升高而增加, 当反应温度为90℃时, 产物全部为3。4c加热时转化为3c。膦加合物3或4在甲醇-水中于封管内150℃加热, 发生P-C键断裂。两者都立体专一性地生成(Z)3-全氟烷基-4-对硝基苯基-3-丁烯酸甲酯(5)。胂加合物3在甲醇-水中回流, 发生As-C键断裂, 生成(Z)-5。对水解机理进行了研究。     

(Z)-2-苯氧(硫)基甲基-2-戊烯-γ-内酯和(Z)-2-苯氧(硫)亚甲基-γ-戊内酯的简便合成

以3-苯氧(硫)基丙炔(1)为原料,经5步反应合成(Z)-2-苯氧(硫)基甲基-2-戊烯-γ-内酯(8)和(Z)-2-苯硫亚甲基-γ-戊内酯(9).合成关键步骤为TMSCl/NaI/H2O/CH3CN体系中化合物(3)的碘氢化和去共轭.     

Design,synthesis and preclinical evaluations of (s)-2-((s)-1-benzyl-2,5-dioxopyrrolidin-3-yl)-3-(4-isopropylphenyl)-2-methylpropanal (succ-5) as cardioprotective,hepatoprotective and lipid lowering molecule. in-vivo and in-silico approaches

In this study, the newly synthesized compound (Succ-5) was analyzed through spectral methods, seen for potential receptor targets via molecular docking, and pre-clinically evaluated for therapeutic effects and safety profile using biochemical and histopathological techniques. The biochemical analysis included assessment of cardiac biomarkers, hepatic enzymes, and lipid profiles, while histopathology included evaluation of cardiac and liver tissues. The toxic dose was determined pre-clinically, followed by dividing albino rats into five treatment groups (each having n = 6). The control group received oral saline for eight days. The 5-FU (5-Fluorouracil) group received oral saline for 8 days and 5-FU (150 mg/kg I.P.) on day 5. The atenolol group was administered with atenolol (20 mg/kg) for 8 days and 5-FU (150 mg/kg I.P.) on day 5. Two groups of rats were administered with the test compound (Succ-5) at doses of 5 mg/kg I.P and 10 mg/kg I.P (for 8-days), followed by 5-FU (150 mg/kg I.P.) on day 5. Elevated serum levels of CK-MB (creatinine kinase myocardial band), cTnI (troponin I), LDH (lactate dehydrogenase), lipid profile, and selected liver enzymes including ALP (alkaline phosphatase), ALT (alanine transaminase), AST (aspartate aminotransferase), BT (bilirubin total) and BD (direct bilirubin) were associated with 5-FU toxicity. After administration of the test compound at the mentioned doses, these biomarkers significantly decreased. Likewise, histological examination revealed 5-FU damaged the heart and hepatic tissues, which were also considerably recovered following administration of the test compound. Immunohistochemistry of heart tissue also revealed the low expression of COX-2 and TNF-α in Succ-5 treated groups compared to toxic group. Dose-response evaluation showed that a dose of 10 mg/kg provided better results than 5 mg/kg. The analysis of binding energy values computed via docking simulations showed that Succ-5 interacts with the human beta2-adrenergic G protein-coupled receptor with a slightly stronger affinity than calcium channel T-type. In conclusion, the histological and biochemical findings revealed that the test compound had significant cardioprotective, hepatoprotective, and lipolytic effects in the 5-FU-induced toxicity.     

胶体介孔二氧化硅增强抗癌药物治疗效果的研究

胶体介孔Si O_2(CMS)是一种具有良好生物相容性、高稳定性和高负载量的药物载体。本文采用带正电荷的CMS作为药物载体负载抗癌药物5F用来抑制鼻咽癌细胞CNE2的生长。实验结果表明,CMS本身对于细胞是无毒的,可通过细胞的内吞作用进入并在细胞中分布。相对于单独的5F,CMS@5F诱导鼻咽癌细胞凋亡的效果明显增强,说明CMS能将5F有效携带至细胞中使其局部浓度增大,促进5F抑制癌细胞生长的效果。     

Nanogold Particles Suppresses 5-Flurouracil-Induced Renal Injury: An Insight into the Modulation of Nrf-2 and Its Downstream Targets,HO-1 and γ-GCS

The development of the field of nanotechnology has revolutionized various aspects in the fields of modern sciences. Nano-medicine is one of the primary fields for the application of nanotechnology techniques. The current study sheds light on the reno-protective impacts of gold nano-particles; nanogold (AuNPs) against 5-flurouracil (5-FU)-induced renal toxicity. Indeed, the use of 5-FU has been associated with kidney injury which greatly curbs its therapeutic application. In the current study, 5-FU injection was associated with a significant escalation in the indices of renal injury, i.e., creatinine and urea. Alongside this, histopathological and ultra-histopathological changes confirmed the onset of renal injury. Both gene and/or protein expression of nuclear factor erythroid 2–related factor 2 (Nrf-2) and downstream antioxidant enzymes revealed consistent paralleled anomalies. AuNPs administration induced a significant renal protection on functional, biochemical, and structural levels. Renal expression of the major sensor of the cellular oxidative status Nrf-2 escalated with a paralleled reduction in the renal expression of the other contributor to this axis, known as Kelch-like ECH-associated protein 1 (Keap-1). On the level of the effector downstream targets, heme oxygenase 1 (HO-1) and gamma-glutamylcysteine synthetase (γ-GCS) AuNPs significantly restored their gene and protein expression. Additionally, combination of AuNPs with 5-FU showed better cytotoxic effect on MCF-7 cells compared to monotreatments. Thus, it can be inferred that AuNPs conferred reno-protective impact against 5-FU with an evident modulatory impact on Nrf-2/Keap-1 and its downstream effectors, HO-1 and γ-GCS, suggesting its potential use in 5-FU regimens to improve its therapeutic outcomes and minimize its underlying nephrotoxicity.     

Facile and regioselective synthesis of novel 2,4-disubstituted-5-fluoropyrimidines as potential kinase inhibitors

2,4-Disubstituted-5-fluoropyrimidine is a biologically active molecular core seen in various anticancer agents such as 5-fluorouracil (5-FU). As part of a programme aimed at discovering kinase inhibitors, routes to two series of novel compounds (5-fluoropyrimidine-2-carboxamides and 5-fluoropyrimidine-4-carboxamides) were successfully executed. For the first series, regioselective substitution at the 4-position of the pyrimidine with an amine (HNR¹R²) was achieved, followed by preparation of the amide at the 2-position. The route to the second series involved introduction of the methoxy protecting group at the 4-position, which allowed subsequent amine substitution to occur at the 2-position. The 4-amide substituent was finally introduced by direct conversion of the 4-methoxy into a 4-chloro group followed by transformation into an amide by palladium catalysis.     

Effect of L-cysteine on plasma concentration and urinary excretion of 1-(tetrahydro-2-furanyl)-5-fluorouracil metabolites

Effects of L-cysteine (CySH) on the plasma concentrations and the urinary excretion of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its metabolites were studied by high performance liquid chromatography in rats. Significantly higher plasma concentrations of FT, 5-fluorouracil (5-FU) and cis-4'-OH-FT were obtained after an oral administration of FT (500 mg/kg) combined orally with CySH (500 mg/kg) when compared to FT alone. The urinary excretions of 5-FU, trans-3'-OH-FT, cis-4'-OH-FT, trans-4'-OH-FT and 4',5'-dehydro-FT significantly decreased up to 12 h but that of alpha-fluoro-beta-alanine significantly increased up to 24 h by the combined administration of CySH. Furthermore, the plasma concentration of 5-FU significantly increased at 0.5 h and its urinary excretion significantly decreased up to 4 h after an intraperitoneal administration of 5-FU (10 mg/kg) combined orally with CySH (500 mg/kg) when compared to 5-FU alone. The urinary pH significantly changed to acidic and the urinary volume significantly increased by the combined administration of CySH, so it was thought that the reabsorption of 5-FU through renal tubules from urine could increase and the increment of the urinary excretion of alpha-fluoro-beta-alanine was caused by this. Then it was suggested that the increase of the plasma concentrations of 5-FU and cis-4'-OH-FT could be attributed to the decrease of their urinary excretions after an administration of FT combined with CySH when compared to FT alone.     

Design,Synthesis, Molecular Docking,and Tumor Resistance Reversal Activity Evaluation of Matrine Derivative with Thiophene Structure

Nasopharyngeal carcinoma (NPC) frequently occurs in Southern China. The main treatments of NPC are chemotherapy and radiotherapy. However, chemo-resistance arises as a big obstacle in treating NPC. Therefore, there is a great need to develop new compounds that could reverse tumor drug resistance. In this study, eight matrine derivatives containing thiophene group were designed and synthesized. Structures of these 8 compounds were characterized by ¹H-NMR, ¹³C-NMR, and high-resolution mass spectrometer (HRMS). The cytotoxicity and preliminary synergistic effects of these 8 compounds were detected against nasopharyngeal carcinoma (NPC) cells and cisplatin-resistant NPC cells (CNE2/CDDP), respectively. Furthermore, the in vivo and in vitro tumor resistance reversal effects of compound 3f were evaluated. Moreover, docking studies were performed in Bclw (2Y6W). The results displayed that compound 3f showed synergistic inhibitory effects with cisplatin against CNE2/CDDP cells proliferation via apoptosis induction. Docking results revealed that compound 3f may exert its effects via inhibiting anti-apoptosis protein Bcl-w.     

(10Z)- and (10E)-19-fluoro-1alpha,25-dihydroxyvitamin D3: an improved synthesis via 19-nor-10-oxo-vitamin D

An efficient synthetic route to (10Z)- and (10E)-19-fluoro-1alpha,25-dihydroxyvitamin D3 was developed. The key feature of this pathway is the introduction of a 19-fluoromethylene group to a (5E)-19-nor-10-oxo-vitamin D derivative. The 10-oxo-compound was obtained via a 1,3-dipolar cycloaddition reaction of (5E)-1alpha,25-dihydroxyvitamin D with in situ generated nitrile oxide followed by ring cleavage of the formed isoxazoline moiety with molybdenum hexacarbonyl. Conversion of the keto group of (5E)-19-nor-10-oxo-vitamin D to the E and Z fluoromethylene group was achieved through a two-step sequence involving a reaction of lithiofluoromethyl phenyl sulfone followed by the reductive desulfonylation of the alpha-fluoro-beta-hydroxy sulfone. The dye-sensitized photoisomerization of the (5E)-19-fluorovitamin D afforded the desired (5Z)-19-fluorovitamin D derivatives, (10Z)- and (10E)-19-fluoro-1alpha,25-dihydroxyvitamin D3.     

An assessment of mucosal damage in vivo: effect of oral pretreatment with 5-fluorouracil on the intestinal first-pass metabolism of salicylamide in rabbits.

An assessment of 5-fluorouracil (5-FU)-induced mucosal damage in vivo by measuring the metabolism of salicylamide (SAM) was investigated in rabbit intestine. The mucosal damage in the intestine 48 h after oral administration of 5-FU (30 mg/kg) was examined using a scanning electron microscope. By the oral pretreatment with 5-FU, the morphological changes of jejunal and ileal mucosa were recognized compared with the control. The intestinal first-pass metabolism of SAM was studied using in situ intestinal sacs with complete mesenteric venous blood collection. The appearance of both SAM and its metabolites into the mesenteric venous blood was measured directly by cannulating the mesenteric vein of exposed intestine and collecting all venous blood draining from the absorbing region. Following oral pretreatment with 5-FU, the appearance of SAM glucuronide (SAMG) in the mesenteric venous blood was significantly increased. The increased blood concentration of SAMG following intraduodenal administration of SAM in vivo was observed in rabbits pretreated with 5-FU orally. However, the blood concentration of SAMG after intravenous administration of SAM was not increased compared with the control. These findings suggest that the change in intestinal first-pass metabolism of SAM may be due to the intestinal mucosal damage by oral pretreatment with 5-FU. The alteration of intestinal first-pass metabolism of a marker compound may be utilized for the assessment of intestinal mucosal damage in vivo.